Leqvio indication
Pro Research Analysisby 
Searched over 200M research papers for "leqvio indication"
Indications for Inclisiran (Leqvio)
Introduction to Inclisiran (Leqvio)
Inclisiran, marketed under the brand name Leqvio, is a groundbreaking small interfering RNA (siRNA) therapeutic developed by Novartis. It is designed to lower cholesterol levels by targeting the mRNA coding for the PCSK9 gene, which plays a crucial role in cholesterol metabolism 134.
Primary Hypercholesterolemia and Mixed Dyslipidemia
Inclisiran is primarily indicated for adults with primary hypercholesterolemia, both heterozygous familial and non-familial, as well as mixed dyslipidemia. It is used as an adjunct to diet and is often combined with statins or other lipid-lowering therapies for patients who cannot achieve their low-density lipoprotein cholesterol (LDL-C) goals with the maximum tolerated statin dose 13.
Statin-Intolerant Patients
For patients who are intolerant to statins or for whom statins are contraindicated, inclisiran can be used alone or in combination with other lipid-lowering therapies. This flexibility makes it a valuable option for a broader range of patients struggling with high cholesterol levels 134.
Administration and Dosage
Inclisiran is administered as a subcutaneous injection, typically by a healthcare professional. The initial dose is followed by a second dose at three months, and subsequent doses are given every six months. This biannual dosing schedule is convenient and ensures sustained cholesterol reduction 13.
Clinical Efficacy and Safety
Clinical trials and real-life data have demonstrated that inclisiran effectively reduces LDL-C levels. In patients receiving combined therapy with a statin, LDL-C reduction was observed as early as one week after the initial dose, with a mean reduction of 40-50% depending on whether they were also on statin therapy . The ORION clinical trials have further validated the safety and efficacy of inclisiran, although ongoing studies like ORION-4 and ORION-8 are expected to provide more long-term data 45.
Adjunct Therapy for Elevated Lipid Levels
Inclisiran has also been approved as an adjunct therapy for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional LDL-C reduction despite maximal statin therapy. This makes it a critical tool in managing patients at high cardiovascular risk 24.
Conclusion
Inclisiran (Leqvio) represents a significant advancement in the treatment of hypercholesterolemia and mixed dyslipidemia, particularly for patients who are statin-intolerant or unable to achieve their LDL-C targets with existing therapies. Its biannual dosing and proven efficacy make it a promising option for long-term cholesterol management. However, further studies are needed to fully understand its long-term impact on cardiovascular morbidity and mortality.
Sources and full results
Most relevant research papers on this topic